Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-binding protein 4 (CABP4) is a member of the calcium-binding protein family characterized by four EF-hand motifs[2]. It is highly expressed at photoreceptor synaptic terminals in the retina, where it modulates the activity of voltage-dependent calcium channels (notably Cav1.3 and Cav1.4), influencing calcium influx and neurotransmitter release[1][3][5]. Disruption of CABP4 impairs synaptic ribbon formation, leading to structural and functional abnormalities in the first retinal synapse and is associated with congenital stationary night blindness type 2B and cone-rod synaptic disorder[1][2][3]. CABP4 is also expressed in the brainstem and other regions, and mutations have been linked in rare instances to epilepsy[3]. While essential for visual and possibly auditory synaptic function, there are currently no known interacting drugs or direct therapeutic targeting of CABP4 reported[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium-binding protein 4 (CABP4).